Literature DB >> 26018172

Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.

Asisa Volz1, Alexandra Kupke2, Fei Song1, Sylvia Jany1, Robert Fux1, Hosam Shams-Eldin2, Jörg Schmidt2, Christin Becker3, Markus Eickmann2, Stephan Becker2, Gerd Sutter4.   

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans. We tested a recombinant modified vaccinia virus Ankara (MVA) vaccine expressing full-length MERS-CoV spike (S) glycoprotein by immunizing BALB/c mice with either intramuscular or subcutaneous regimens. In all cases, MVA-MERS-S induced MERS-CoV-specific CD8(+) T cells and virus-neutralizing antibodies. Vaccinated mice were protected against MERS-CoV challenge infection after transduction with the human dipeptidyl peptidase 4 receptor. This MERS-CoV infection model demonstrates the safety and efficacy of the candidate vaccine.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26018172      PMCID： PMC4524222          DOI： 10.1128/JVI.00614-15

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  29 in total

1.  Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.

Authors:  Sharon E Frey; Patricia L Winokur; Heather Hill; Johannes B Goll; Paul Chaplin; Robert B Belshe
Journal:  Vaccine       Date:  2014-03-06       Impact factor: 3.641

2.  Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development.

Authors:  Lanying Du; Guangyu Zhao; Zhihua Kou; Cuiqing Ma; Shihui Sun; Vincent K M Poon; Lu Lu; Lili Wang; Asim K Debnath; Bo-Jian Zheng; Yusen Zhou; Shibo Jiang
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

3.  Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

Authors:  Stephen R Walsh; Marissa B Wilck; David J Dominguez; Elise Zablowsky; Shringkhala Bajimaya; Lisa S Gagne; Kelly A Verrill; Jane A Kleinjan; Alka Patel; Ying Zhang; Heather Hill; Aruna Acharyya; David C Fisher; Joseph H Antin; Michael S Seaman; Raphael Dolin; Lindsey R Baden
Journal:  J Infect Dis       Date:  2013-03-12       Impact factor: 5.226

4.  Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.

Authors:  Fei Song; Robert Fux; Lisette B Provacia; Asisa Volz; Markus Eickmann; Stephan Becker; Albert D M E Osterhaus; Bart L Haagmans; Gerd Sutter
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

Review 5.  Clinical applications of attenuated MVA poxvirus strain.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Juan García-Arriaza; Mariano Esteban
Journal:  Expert Rev Vaccines       Date:  2013-10-30       Impact factor: 5.217

Review 6.  Middle East respiratory syndrome coronavirus: epidemiology and disease control measures.

Authors:  Jaffar A Al-Tawfiq; Ziad A Memish
Journal:  Infect Drug Resist       Date:  2014-11-03       Impact factor: 4.003

7.  Animal models and vaccines for SARS-CoV infection.

Authors:  Anjeanette Roberts; Elaine W Lamirande; Leatrice Vogel; Jadon P Jackson; Christopher D Paddock; Jeannette Guarner; Sherif R Zaki; Timothy Sheahan; Ralph Baric; Kanta Subbarao
Journal:  Virus Res       Date:  2007-05-11       Impact factor: 3.303

8.  Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.

Authors:  Cuiqing Ma; Lili Wang; Xinrong Tao; Naru Zhang; Yang Yang; Chien-Te K Tseng; Fang Li; Yusen Zhou; Shibo Jiang; Lanying Du
Journal:  Vaccine       Date:  2014-09-19       Impact factor: 3.641

Review 9.  Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.

Authors:  Arwen F Altenburg; Joost H C M Kreijtz; Rory D de Vries; Fei Song; Robert Fux; Guus F Rimmelzwaan; Gerd Sutter; Asisa Volz
Journal:  Viruses       Date:  2014-07-17       Impact factor: 5.048

10.  Calling for rapid development of a safe and effective MERS vaccine.

Authors:  Peter J Hotez; Maria Elena Bottazzi; Chien-Te K Tseng; Bin Zhan; Sara Lustigman; Lanying Du; Shibo Jiang
Journal:  Microbes Infect       Date:  2014-06-12       Impact factor: 2.700
View more
  89 in total

1.  Preventing drug-resistant tuberculosis transmission.

Authors:  Anastasia Koch; Helen Cox
Journal:  Lancet Infect Dis       Date:  2019-11-26       Impact factor: 25.071

Review 2.  Prospects for a MERS-CoV spike vaccine.

Authors:  Yusen Zhou; Shibo Jiang; Lanying Du
Journal:  Expert Rev Vaccines       Date:  2018-08-09       Impact factor: 5.217

Review 3.  Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.

Authors:  Heeyoun Cho; Jean-Louis Excler; Jerome H Kim; In-Kyu Yoon
Journal:  Hum Vaccin Immunother       Date:  2017-11-29       Impact factor: 3.452

4.  One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.

Authors:  Christoph Wirblich; Christopher M Coleman; Drishya Kurup; Tara S Abraham; John G Bernbaum; Peter B Jahrling; Lisa E Hensley; Reed F Johnson; Matthew B Frieman; Matthias J Schnell
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

5.  Lectin Affinity Plasmapheresis for Middle East Respiratory Syndrome-Coronavirus and Marburg Virus Glycoprotein Elimination.

Authors:  Benjamin Koch; Patricia Schult-Dietrich; Stefan Büttner; Bijan Dilmaghani; Dario Lohmann; Patrick C Baer; Ursula Dietrich; Helmut Geiger
Journal:  Blood Purif       Date:  2018-04-26       Impact factor: 2.614

6.  Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.

Authors:  Mohamad Hesam Shahrajabian; Wenli Sun; Qi Cheng
Journal:  Hum Vaccin Immunother       Date:  2020-08-12       Impact factor: 3.452

Review 7.  Animal models of Middle East respiratory syndrome coronavirus infection.

Authors:  Neeltje van Doremalen; Vincent J Munster
Journal:  Antiviral Res       Date:  2015-07-17       Impact factor: 5.970

Review 8.  Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control.

Authors:  Prasannavenkatesh Durai; Maria Batool; Masaud Shah; Sangdun Choi
Journal:  Exp Mol Med       Date:  2015-08-28       Impact factor: 8.718

9.  Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines.

Authors:  Chuan Wang; Matthew Hart; Cecilia Chui; Augustine Ajuogu; Iona J Brian; Simone C de Cassan; Persephone Borrow; Simon J Draper; Alexander D Douglas
Journal:  J Immunol       Date:  2016-07-13       Impact factor: 5.422

10.  Middle East respiratory syndrome: current status and future prospects for vaccine development.

Authors:  Lanying Du; Shibo Jiang
Journal:  Expert Opin Biol Ther       Date:  2015-09-28       Impact factor: 4.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.